The Order Of Trust
The bottom line: The U.S. government is unlikely to approve any psychedelic medicine, or loosen the laws around these drugs, until one specific agency — the FDA, the part of government that decides if a medicine is safe enough to sell — gives its blessing first. For ordinary people waiting on treatments like MDMA for trauma, that means relief is coming through a careful front door, not a shortcut. The waiting is real, but so is the forward motion.
What the data is actually showing today is a system that has quietly agreed on the order things must happen in. The swarm's strongest reading, at 74 percent confidence, is that the FDA will not approve any psychedelic medicine until the makers fix a stubborn problem and re-file their application. The problem is simple to picture: in the trials, people could often tell whether they got the real drug or a fake pill, because the real drug makes you feel something powerful. That makes it harder to prove the medicine itself — and not just hope — caused the healing. Real-world results from clinics can help fill the gap, but the reviewers say those results can add to the proof, not replace it. Alongside this, agents expect a panel of outside experts to be gathered again before any final MDMA decision — a kind of public second opinion the FDA leans on when the science is contested.
The deeper current beneath all of this is a chain of trust, each link waiting on the one before it. Congress won't pass new laws first. The DEA, the agency that polices controlled drugs, won't loosen its grip first. Both are waiting for the FDA. The swarm puts this "everyone waits for the FDA" pattern at over 70 percent. There's a second thread too: scientists keep learning stunning things about how these drugs work in the brain, faster than they can prove those drugs reliably heal people in careful trials. That gap is widening, not closing. Meanwhile the DEA is keeping a watchful eye on ketamine sent to people's homes through online clinics — a real medicine, but one that's hard to track once it leaves the building. None of this is the system blocking the door. It's the system deciding the door must open in a trustworthy order, so that whatever comes through can't be torn back out later.
For the human beings inside this story, what becomes possible is a healing that holds. Think of the veteran carrying trauma that no pill has touched, the family watching someone they love disappear inside depression, the person who has tried everything. The waiting is heavy, and it is fair to be tired of it. But the highest path genuinely available right now is the one that turns hope into something solid — a treatment that a doctor can hand over with confidence, that insurance might cover, that won't be yanked away after one bad headline. The careful door is slower. It is also the only door that stays open.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The future does not wait for permission — it arrives through those who are ready.
74%
No psychedelic drug will get US approval in 2026
The FDA (the US drug regulator) won't approve any psychedelic medicine next year unless companies completely redo their applications to fix a specific problem: participants in trials can usually tell whether they got the real drug or a placebo, which muddies the results. No company has fixed this yet, so approval is off the table for now. This delays access to potentially life-changing treatments for people with depression, PTSD, and addiction.
→ The FDA won't approve any psychedelic drug in 2026 because companies haven't solved the problem of trial participants knowing whether they got the real drug.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA will not approve any psychedelic NDA in 2026 absent a complete resubmission addressing functional unblinding.. Functional unblinding is a known, documented threat to efficacy data integrity in psychedelic trials. RWE can supplement but cannot substitute for blinded controlled evidence under current FDA standards. No pending NDA has resolved this, making a 2026 approval unlikely.
68%
DEA will crack down on at-home ketamine prescribed over video call
Ketamine is a legal anesthetic that doctors can prescribe off-label for depression, and a wave of telehealth companies now ship it to patients' homes after a video call. The DEA (the drug enforcement agency) has flagged this as a serious diversion risk — meaning the drug could end up misused or sold. By mid-2027, expect the DEA to issue at least one formal warning, rule, or enforcement action specifically targeting this kind of at-home ketamine prescribing.
→ The DEA will likely take formal action against the practice of prescribing ketamine for home delivery via video-call appointments before mid-2027.
Resolves: 2027-06-22 · USA
REGULATION
the precise call ▾
DEA will maintain Schedule I classification for psychedelics and issue at least one scrutiny action on telehealth ketamine prescribing by 2027-06-22.. DEA will not preempt FDA on scheduling, but at-home subcutaneous/telehealth ketamine presents a diversion-control concern DEA has flagged repeatedly. An enforcement notice, proposed rule, or guidance on telehealth ketamine within the window is the falsifiable trigger.
74%
Psychedelics will stay in the most restricted drug category through 2026
In the US, psychedelics like psilocybin and MDMA sit in Schedule I — the government's most restricted drug category, meaning they're treated as having no accepted medical use and high abuse potential. The DEA (the agency that enforces drug laws) almost always waits for the FDA to approve a drug before loosening those restrictions. Since no FDA approval is coming in 2026, the scheduling won't change either.
→ Psychedelics will stay in the US's most restricted drug category through 2026 because drug law changes follow FDA approval, not the other way around.
Resolves: 2026-12-19 · USA
LEGISLATION
the precise call ▾
No federal rescheduling of any Schedule I psychedelic will occur before FDA approval, through 2026.. Three agents (DEA, legislator, FDA reviewer) concur that agencies and Congress sequence rescheduling after FDA action, not before. DEA historically follows FDA/HHS scheduling recommendations. The lone dissent (MAPS researcher) reflects advocacy optimism rather than procedural reality.
70%
Congress will only fund small veteran-focused psychedelic pilot programs
Rather than passing a broad law to change how psychedelics are classified, Congress will focus any psychedelic action narrowly on military veterans — a group with strong political sympathy on both sides of the aisle. Full rescheduling legislation has almost no political momentum, but small pilot programs for veterans with PTSD (post-traumatic stress disorder) give politicians a safe, popular thing to support. This shapes who gets early access — mostly veterans, not the general public.
→ Congress will only touch psychedelics through small, politically safe veteran programs — a full national policy change is not on the table.
Resolves: 2027-06-22 · USA
LEGISLATION
the precise call ▾
Congress will not pass standalone federal psychedelic rescheduling legislation before FDA approval; any advancing measure will be veteran-focused pilot programs.. Veteran framing provides bipartisan cover; standalone rescheduling lacks constituent support. Falsifiable: passage of a non-veteran-framed standalone rescheduling bill before FDA approval would break this prediction.
69%
No psychedelic treatment approved using only real-world patient data by mid-2027
Some advocates argue that real-world reports — stories from patients and clinicians, observational data — should be enough to get psychedelic therapies approved. The FDA disagrees: it requires carefully controlled studies where you compare a treatment group to a placebo group under strict conditions. No psychedelic therapy will clear that bar using only real-world evidence by June 2027. This matters because it means approval takes longer and costs much more.
→ The FDA will not approve any psychedelic treatment based mainly on patient reports or real-world data — only rigorous controlled studies count.
Resolves: 2027-06-22 · USA
RESEARCH
the precise call ▾
No psychedelic therapy will receive FDA approval based primarily on real-world evidence or case series by 2027-06-22.. Mechanistic neuroscience continues outpacing validated controlled clinical translation; RWE and case series do not meet the controlled-evidence bar for approval. Falsifiable: an FDA approval citing RWE/case series as primary evidence within the window would refute it.